Intech Investment Management LLC Acquires New Stake in OmniAb, Inc. (NASDAQ:OABI)

Intech Investment Management LLC purchased a new position in OmniAb, Inc. (NASDAQ:OABI) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 16,437 shares of the company’s stock, valued at approximately $70,000.

A number of other hedge funds also recently bought and sold shares of OABI. Towerview LLC raised its holdings in OmniAb by 114.0% in the 2nd quarter. Towerview LLC now owns 535,000 shares of the company’s stock worth $2,006,000 after acquiring an additional 285,000 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of OmniAb by 6.9% in the second quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company’s stock worth $11,296,000 after purchasing an additional 194,835 shares during the last quarter. Rice Hall James & Associates LLC lifted its holdings in shares of OmniAb by 6.4% during the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock valued at $11,515,000 after purchasing an additional 163,038 shares in the last quarter. Isthmus Partners LLC boosted its position in shares of OmniAb by 37.2% during the second quarter. Isthmus Partners LLC now owns 528,385 shares of the company’s stock valued at $1,981,000 after buying an additional 143,387 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new stake in OmniAb in the 2nd quarter worth about $449,000. Institutional investors own 72.08% of the company’s stock.

OmniAb Stock Performance

Shares of OmniAb stock opened at $4.02 on Monday. The stock has a market cap of $567.70 million, a P/E ratio of -6.48 and a beta of -0.14. The stock’s fifty day moving average is $4.04 and its 200 day moving average is $4.20. OmniAb, Inc. has a one year low of $3.56 and a one year high of $6.72.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Royal Bank of Canada restated an “outperform” rating and set a $7.00 target price on shares of OmniAb in a research note on Friday, August 16th. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of OmniAb in a research note on Thursday, November 14th. Finally, Benchmark reiterated a “buy” rating and set a $8.00 price objective on shares of OmniAb in a research report on Thursday, November 14th.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.